PMID- 28218263
OWN - NLM
STAT- MEDLINE
DCOM- 20170417
LR  - 20220317
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 13
IP  - 5
DP  - 2017 May
TI  - Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney 
      disease.
PG  - 297-310
LID - 10.1038/nrneph.2017.16 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is caused by an accumulation of fat in 
      the liver; the condition can progress over time to increase the risk of 
      developing cirrhosis, end-stage liver disease and hepatocellular carcinoma. The 
      prevalence of NAFLD is increasing rapidly owing to the global epidemics of 
      obesity and type 2 diabetes mellitus (T2DM), and NAFLD has been predicted to 
      become the most important indication for liver transplantation over the next 
      decade. It is now increasingly clear that NAFLD not only affects the liver but 
      can also increase the risk of developing extra-hepatic diseases, including T2DM, 
      cardiovascular disease and chronic kidney disease (CKD), which have a 
      considerable impact on health-care resources. Accumulating evidence indicates 
      that NAFLD exacerbates insulin resistance, predisposes to atherogenic 
      dyslipidaemia and releases a variety of proinflammatory factors, prothrombotic 
      factors and profibrogenic molecules that can promote vascular and renal damage. 
      Furthermore, communication or 'crosstalk' between affected organs or tissues in 
      these diseases has the potential to further harm function and worsen patient 
      outcomes, and increasing amounts of evidence point to a strong association 
      between NAFLD and CKD. Whether a causal relationship between NAFLD and CKD exists 
      remains to be definitively established.
FAU - Targher, Giovanni
AU  - Targher G
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale 
      Stefani 1, 37126 Verona, Italy.
FAU - Byrne, Christopher D
AU  - Byrne CD
AD  - Nutrition and Metabolism, Faculty of Medicine, University of Southampton.
AD  - Southampton National Institute for Health Research Biomedical Research Centre, 
      University Hospital Southampton, Southampton General Hospital, Tremona Road, 
      Southampton SO16 6YD, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170220
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
SB  - IM
MH  - Diabetes Mellitus, Type 2/etiology
MH  - Endothelial Cells/physiology
MH  - Gastrointestinal Microbiome
MH  - Humans
MH  - Non-alcoholic Fatty Liver Disease/*complications/epidemiology/therapy
MH  - Prevalence
MH  - Renal Insufficiency, Chronic/*etiology
EDAT- 2017/02/22 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/02/21 06:00
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/04/18 06:00 [medline]
PHST- 2017/02/21 06:00 [entrez]
AID - nrneph.2017.16 [pii]
AID - 10.1038/nrneph.2017.16 [doi]
PST - ppublish
SO  - Nat Rev Nephrol. 2017 May;13(5):297-310. doi: 10.1038/nrneph.2017.16. Epub 2017 
      Feb 20.